Home Liquid Biopsy and ctDNA Blood-Based Multi-Cancer Early Detection Test: Cancer Signals, Screening, and Follow-Up

Blood-Based Multi-Cancer Early Detection Test: Cancer Signals, Screening, and Follow-Up

By
Vita Library
-
1
Learn how blood-based multi-cancer early detection tests find cancer signals, what positive and negative results mean, and what follow-up may involve.

A blood-based multi-cancer early detection test, often called an MCED or MCD test, looks for biological signals that may come from one of several cancers at the same time. Most current approaches analyze cell-free DNA in plasma, including cancer-related methylation patterns, mutations, fragment patterns, or combinations of DNA and protein markers. A positive result does not diagnose cancer. It means the test detected a signal that needs targeted diagnostic follow-up. A negative result also does not rule out cancer, especially when a tumor is small or sheds little material into the blood. These tests are promising because they may detect cancers that lack routine screening programs, but their effect on cancer mortality is still being studied. They should not replace established screening such as mammography, cervical screening, colorectal screening, or lung cancer screening when those tests are recommended.

  • A “cancer signal detected” result means further testing is needed, not that cancer is confirmed.
  • There is no universal normal blood level for an MCED test; results are usually reported as signal detected or not detected.
  • A negative MCED result cannot exclude cancer and should not delay evaluation of concerning symptoms.
  • MCED testing does not replace guideline-recommended screening for breast, cervical, colorectal, lung, or other cancers.
  • Follow-up after a positive result is usually directed by the predicted cancer signal origin and may include imaging, laboratory tests, endoscopy, or biopsy.

Table of Contents

What Multi-Cancer Blood Tests Measure

Multi-cancer early detection tests look for patterns in blood that are associated with cancer. They are not one single laboratory method. Different products may examine different biomarkers, use different algorithms, cover different cancer types, and report results in different ways.

A common starting material is cell-free DNA (cfDNA). Everyone has small DNA fragments circulating in plasma, mostly released by normal blood cells. In a person with cancer, a small portion may come from tumor cells. That tumor-derived portion is called circulating tumor DNA, or ctDNA. A cell-free DNA cancer test may therefore contain both ordinary cfDNA and a much smaller cancer-associated signal.

Modern MCED assays may evaluate one or more of the following:

  • DNA methylation: chemical tags on DNA that help regulate gene activity. Cancer cells often have abnormal methylation patterns.
  • Somatic mutations: acquired DNA changes found in tumor cells but not inherited through the germline.
  • Fragmentomics: the size, ends, distribution, and genome-wide pattern of DNA fragments. These features can differ between normal and cancer-derived DNA.
  • Copy-number changes: gains or losses of larger chromosome regions.
  • Protein biomarkers: circulating proteins that may rise with particular cancers.
  • Combined signatures: algorithms that integrate several signal types to improve cancer detection or estimate where a signal originated.

This differs from a conventional liquid biopsy test ordered for someone who already has cancer. In advanced cancer, the goal is often to identify an actionable mutation, monitor treatment, or investigate resistance. MCED testing is aimed at people without a known active cancer and asks a harder question: is there evidence of an otherwise unsuspected cancer somewhere in the body?

That difference matters because the concentration of tumor-derived material can be extremely low before a cancer becomes large enough to cause symptoms or appear clearly on imaging. A screening test must also maintain very high specificity. Even a small false-positive rate can lead to many diagnostic workups when millions of healthy people are tested.

How MCED Results Are Reported and What They Mean

Most MCED tests do not give a universal numeric “normal range.” Instead, they generally classify the result as cancer signal detected or cancer signal not detected. Some also provide a predicted cancer signal origin, such as lung, colon/rectum, pancreas, ovary, lymphoid tissue, or another anatomic site.

A cancer signal origin is a prediction, not a diagnosis. It tells the clinician where the molecular pattern most resembles cancer and where to begin the diagnostic evaluation. It can be correct, incorrect, or indeterminate.

A positive result

A positive result means the assay crossed its predefined threshold for a cancer-associated molecular pattern. The next step is diagnostic testing. The probability that cancer is truly present depends on several factors, including the specific assay, the person’s age and cancer risk, and how common cancer is in the tested population.

This is where positive predictive value, or PPV, becomes important. PPV answers the practical question, “Among people with a positive result, how many actually have cancer?” It is not the same as sensitivity or specificity. In the prospective PATHFINDER study of one methylation-based MCED approach in adults aged 50 years or older, 92 of 6,621 people had a cancer signal detected; 35 of those 92 were diagnosed with cancer. That produced a PPV of about 38% for the study version of the assay. A refined version reported a PPV around 43%.

Those numbers should not be generalized to every test. Different assays, populations, and follow-up protocols produce different performance.

A negative result

A negative result means the test did not identify a signal above its reporting threshold. It does not mean the person is cancer-free. Early cancers can shed very little ctDNA. Some tumor types release less DNA into plasma than others, and a blood sample captures only a small snapshot of what is circulating at that moment.

A negative result is therefore not a reason to ignore a breast lump, unexplained bleeding, persistent cough, unintentional weight loss, new neurologic symptoms, or another concerning change. Symptoms require their own clinical evaluation regardless of an MCED result.

Accuracy, Early-Stage Detection, and Important Limitations

MCED accuracy is best understood by separating specificity, sensitivity, and stage-specific sensitivity. High specificity helps minimize false alarms. Sensitivity measures how often a test detects cancer when cancer is actually present. Stage-specific sensitivity asks how well the assay performs in stage I, II, III, or IV disease.

Published studies commonly show that sensitivity rises as cancer stage advances. That is biologically plausible: larger and more advanced tumors often release more tumor DNA or other biomarkers into the bloodstream. Unfortunately, the greatest potential benefit of screening comes from finding cancers while they are still small and curable, so lower stage I sensitivity is an important limitation.

A 2025 systematic literature review found substantial variation across blood-based MCED platforms. Reported performance depended on the test, cancer mix, study design, stage distribution, and how cancer status was confirmed. Across evaluated studies, specificity was often high, while sensitivity varied widely and generally fell for earlier-stage disease.

Several other limitations deserve attention:

  • False positives can trigger a diagnostic cascade. Imaging, endoscopy, repeated blood tests, specialist visits, and occasionally invasive procedures may be needed before cancer is excluded.
  • False negatives can create false reassurance. An MCED test may miss an existing cancer, particularly a small or low-shedding tumor.
  • Cancer signal origin can be wrong. A predicted organ guides the search but cannot determine the diagnosis by itself.
  • Overdiagnosis is possible. Screening may identify some cancers that would never have caused illness during a person’s lifetime.
  • Incidental findings can occur. Follow-up scans can reveal benign nodules, cysts, enlarged lymph nodes, or other abnormalities that require additional evaluation.
  • Performance estimates are population-dependent. Results from case-control studies that compare known cancer cases with healthy controls can look better than results from real-world screening populations.

MCED tests also should not be confused with the Galleri test specifically. Galleri is one commercial MCED approach, whereas MCED is the broader category. Other platforms use different biomarkers and algorithms, including mutation- and protein-based strategies such as the research platform described in the CancerSEEK test literature.

As of September 2026, no MCED test has received FDA authorization for population cancer screening in the United States. Some are available as laboratory-developed tests, while large studies are still evaluating whether their use improves outcomes enough to outweigh harms and costs.

Who Might Consider Testing and Who Should Be Cautious

There is no universally recommended group that should receive routine MCED screening. Major questions remain about the ideal starting age, screening interval, high-risk populations, follow-up pathways, cost-effectiveness, and whether testing lowers cancer mortality.

Commercial testing has largely focused on adults at an age when cancer incidence begins to rise. A clinician may discuss MCED testing with a patient who understands that the test is an additional screening option with uncertain long-term benefit, not a replacement for established care.

A thoughtful discussion should include personal cancer risk, family history, smoking history, prior cancers, inherited cancer syndromes, current symptoms, life expectancy, willingness to undergo follow-up procedures, and access to specialists if the result is positive.

Testing deserves particular caution when a person expects a negative result to provide reassurance that no cancer exists. It also may be less useful when someone would not pursue additional imaging, biopsy, or treatment after a positive result. Screening only has potential value when abnormal findings can be evaluated and clinically meaningful disease can be treated.

People with active symptoms generally need a diagnostic evaluation, not an MCED screening test. For example, iron-deficiency anemia, rectal bleeding, a suspicious imaging finding, or a new palpable mass should be investigated with established diagnostic pathways. An MCED result should not be used to postpone biopsy or organ-specific testing.

People with a known cancer may need a different form of blood testing. A circulating tumor DNA test can be designed to profile tumor mutations, assess molecular residual disease, or monitor treatment rather than screen for multiple new cancers.

What Happens After a Positive Result

A positive MCED result should lead to an organized diagnostic workup rather than immediate assumptions about cancer. The exact pathway depends on the test report, the predicted signal origin, medical history, physical examination, and any symptoms or prior imaging.

A common sequence is:

  1. Confirm the report details. The clinician reviews whether a cancer signal was detected, which origin was predicted, and whether the laboratory recommends a specific evaluation pathway.
  2. Review symptoms and risk factors. New symptoms may change the urgency or type of diagnostic testing.
  3. Order focused diagnostic tests. These may include organ-specific imaging, CT, MRI, ultrasound, mammography, endoscopy, blood tests, or specialist examination.
  4. Biopsy a suspicious lesion when appropriate. A tissue diagnosis usually remains necessary before cancer treatment starts.
  5. Resolve discordant findings. If initial testing is unrevealing but suspicion remains, additional imaging, repeat evaluation, or short-interval follow-up may be considered.

The predicted origin is useful because an unrestricted whole-body search can be inefficient and can uncover many unrelated incidental findings. In PATHFINDER, participants with positive results often underwent imaging and laboratory testing, and diagnostic resolution sometimes took weeks to months. False-positive results generally took longer to resolve than true-positive results.

Do not interpret “positive” as “stage I cancer found.” MCED tests do not directly stage cancer. Staging requires conventional diagnostic imaging, pathology, and sometimes surgery or other procedures.

If a positive result is followed by a negative workup, the person and clinician should document what was evaluated and what follow-up is planned. There is no single evidence-based protocol that fits every unresolved positive result. Repeat testing should not substitute for a careful clinical assessment.

Negative Results and Standard Cancer Screening

A negative MCED result should be viewed as one piece of information, not an all-clear certificate. The most important practical rule is simple: continue every standard cancer screening test for which you are eligible.

That may include mammography for breast cancer, cervical cancer screening, colorectal cancer screening, and low-dose CT for people who meet lung cancer screening criteria. Prostate cancer screening decisions may involve shared decision-making based on age and risk. People with inherited cancer syndromes or strong family histories may need specialized surveillance beyond population guidelines.

Why keep standard screening after a negative MCED test? Organ-specific programs have been developed around defined populations, intervals, diagnostic pathways, and evidence of benefit. MCED tests have not yet demonstrated that they can safely replace those programs.

Timing also matters. A blood test represents a moment in time. A cancer that sheds too little signal today may become detectable later, and a new cancer can arise after the blood draw. That is one reason ongoing trials are studying repeat testing intervals rather than assuming a single test provides lasting protection.

A negative result also should not alter evaluation of symptoms. If a person develops persistent abdominal pain, abnormal bleeding, difficulty swallowing, a new lump, progressive shortness of breath, unexplained weight loss, or another concerning symptom, the next step is clinical assessment. Waiting for the next annual MCED test could delay diagnosis.

Questions to Ask Before Getting an MCED Test

The quality of the decision depends on understanding what will happen after the blood draw. Before testing, ask the clinician or testing service several practical questions:

  • Which cancer types does this assay attempt to detect, and which does it detect poorly?
  • What biomarkers does it measure: methylation, mutations, proteins, fragment patterns, or a combination?
  • What are its sensitivity and specificity in an asymptomatic screening population similar to me?
  • What is the reported PPV, and how often do positive results lead to a confirmed cancer diagnosis?
  • Does the test predict cancer signal origin, and how accurate is that prediction?
  • What diagnostic pathway is recommended if the result is positive?
  • Who coordinates follow-up, and which costs may not be covered by insurance?
  • What should happen if the test is positive but imaging and other tests do not find cancer?
  • Which routine screening tests must I continue regardless of the result?

Also ask whether the laboratory has clear quality standards and whether the report explains limitations in plain language. A screening test is only as useful as the system around it. Access to appropriate follow-up, pathology, imaging, and specialist care matters as much as the blood draw itself.

MCED technology is moving quickly. Newer assays may improve sensitivity, reduce false-positive results, or better identify the tissue of origin. The central evidence question, however, remains unchanged: does adding the test to standard care help people live longer or healthier lives without causing disproportionate harm from unnecessary investigations? Large prospective and randomized studies are designed to answer that question.

Cost and access are part of that decision as well. The price of the blood test may be only one component. A positive result can create additional costs for imaging, specialist consultations, endoscopy, biopsy, anesthesia, pathology, travel, and time away from work. Insurance coverage can vary between the screening test and the diagnostic workup that follows. Before ordering the test, it is reasonable to ask both who pays for the assay and how follow-up services are handled.

It is also useful to decide in advance how you would respond to uncertainty. Some positive results are resolved quickly; others may lead to a period in which no cancer is found but the clinician remains concerned. Knowing that possibility beforehand can make the process less confusing. An MCED test is therefore best treated as the first step in a possible diagnostic pathway, not as a stand-alone answer.

References

Disclaimer

Multi-cancer early detection testing is an evolving area of cancer screening and is not a substitute for medical evaluation, diagnostic testing, or guideline-recommended cancer screening. A positive result requires clinical follow-up, while a negative result cannot rule out cancer. Discuss individual risks, benefits, limitations, and follow-up plans with a qualified health professional.

RELATED ARTICLESMORE FROM AUTHOR